• •								
(REV. 10-2000)	DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER						
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)		A-68285/RMS/DHR						
CONCERNING A FILIN	U.S. APPLICATION NO. (If known, sect 37 C.F.R. 1.5) 09/762491							
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/US99/17776	06 August 1999 (06.08.99)	06 August 1998 (06.08.98)						
TITLE OF INVENTION								
Novel Apoptosis Proteins								
APPLICANT(S) FOR DO/EO/US								
Rigel Pharmaceuticals, Inc.								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1.  This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2. This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.								
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).								
4. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).								
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
a.   is attached hereto (required only if not communicated by the International Bureau).								
b. Land has been communicated by the International Bureau. (See enclosed form PCT/IB/308)								
b. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).  An English language translation of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))  a.   are attached hereto (required only if not communicated by the International Bureau).  b.   have been communicated by the International Bureau.								
An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))								
b. have been communicated by	a. $\square$ are attached hereto (required only if not communicated by the International Bureau).  b. $\square$ have been communicated by the International Bureau.							
c. have not been made; howeve	c. $\square$ have not been made; however, the time limit for making such amendments has NOT expired.							
c. have not been made; howeve d. have not been made and will  8. An English language translation of the	d. A have not been made and will not be made.							
8. An English language translation of the	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
0. An English language translation of the annexes to the International Preliminary Examination Report under								
PCT Article 36 (35 U.S.C. 371(c)(5)).								
Items 11 to 16 below concern other document(s) or information included:								
11.   An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.	•						
2. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
3. A FIRST preliminary amendment.								
☐ A SECOND or SUBSEQUENT prelin	ninary amendment.							
4. A substitute specification.								
15. A change of power of attorney and/or address letter.								
6.  Other items or information:								

U.S. APPLICATION NO. (If known	7762	491	INTERNATIONAL APPLICATI PCT/US99/177		ATTORNEYS DOCKET NUMBER A-68285/RMS/DHR		
17. X The following fees are submitted:					CALCULATIONS	PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):  Neither international preliminary examination fee (37 CFR 1.482)  nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  and International Search Report not prepared by the EPO or JPO							
USPTO but International Search Report prepared by the EPO or JPO							
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)						Name of the Control o	
ENTER APPROPRIATE BASIC FEE AMOUNT =					\$750.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than muths from the earliest claimed priority date (37 CFR 1.492(e)).					\$130.00		
CLAIMS	·	ER FILED	NUMBER EXTRA	RATE			
Total claims	26	-20 =	6	X \$18.00	108.00		
Independent claims	- 4	-3 =	1	X \$80.00	80.00		
Multiple dependent claims (if applicable) + \$270.00					\$270.00		
TOTAL OF ABOVE CALCULATIONS =					1,338.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by					\$669.00		
SUBTOTAL =					669.00		
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).					\$		
TOTAL NATIONAL FEE =					669.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$		
TOTAL FEES ENCLOSED =					669.00		
					Amount to be: refunded	\$	
					charged	\$	
<ul> <li>a. A check in the amount of \$ 669.00 to cover the above fees is enclosed.</li> <li>b. Please charge my Deposit Account No. 06-1300 in the amount of \$ to cover the above fees.</li> </ul>							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No.							

PATENT Attorney Docket No.: A-68285/RMS/DHR

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ying Luo, et al.

**NATIONAL PHASE ENTRY OF:** 

PCT/US99/17776

Serial No.:

Not Yet Assigned

Filed:

Herewith

For:

Novel Apoptosis Proteins

Assistant Commissioner for Patents **BOX PCT**Washington, DC 20231

Sir:

## **EXPRESS MAIL CERTIFICATION UNDER 37 CFR §1.10**

I hereby certify that this New Application and the documents listed below and referred to as enclosed herein are being deposited with the United States Postal Service on this date <u>February 6, 2001</u> in an envelope bearing "Express Mail Post Office To Addressee" Mailing Label Number <u>EL 605 085 256 US</u> addressed to: Assistant Commissioner for Patents **Box PCT**, Washington, D.C. 20231.

Vincent Diaz

Person Mailing

Signature

The following documents are enclosed herein for filing in the aboveidentified new application:

- 1. Transmittal Letter to the U.S. Designated/Elected Office;
- 2. IB/308;

JC03 Rec'd PCT/PTO 0 6 FEB 2001

Serial No.: Not Assigned Filed: **HEREWITH** 

- **Preliminary Amendment** 3.
- 4. Our check in the amount of \$669.00

Respectfully submitted,

FLEHR HOHBACH TEST **ALBRITTON & HERBERT LLP** 

Robin M. Silva Reg. No. 38,304

FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP 4 Embarcadero Center, Suite 3400 San Francisco, CA 94111 Telephone: (415) 781-1989

Dated: 6 February 2001